Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 27 Issue 3, March 2009

Artist's impression of a U1 adaptor oligonucleotide (orange) recruiting the U1 snRNP (snRNa in purple) to the 3' end of a target pre-mRNA (blue). Goraczniak et al. show that the resulting inhibition of transcript polyadenylation silences expression of the target gene (p 257). Credit: Ken Eward © Biografx, with data provided by Holger Stark.

Volume 27 Issue 3

Subscribe

Editorial

  • Contrary to Genentech's claims, turning over all in vitro diagnostics to the US Food and Drug Administration (FDA) is the wrong approach to achieve better clinical validation of tests.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Profile

  • One of the most pioneering protein engineers of his generation is also a serial entrepreneur with a flair for spotting new business opportunities.

    • Crispin Littlehales
    Profile
Top of page ⤴

Data Page

Top of page ⤴

News Feature

Top of page ⤴

Correspondence

Top of page ⤴

Commentary

Top of page ⤴

Feature

  • The Obama administration looks to be a welcome shot in the arm for the scientific endeavor, but the current economic crisis is likely to keep several issues of key interest to biotech firmly on the back burner.

    • Jeffrey L Fox
    Feature
Top of page ⤴

Patents

Top of page ⤴

News & Views

Top of page ⤴

Primer

  • Only a subset of genetic variants can be examined in genome-wide surveys for genetic risk factors. How can a fixed set of markers account for the entire genome by acting as proxies for neighboring associations?

    • Eran Halperin
    • Dietrich A Stephan

    Collection:

    Primer
Top of page ⤴

Article

  • Goraczniak et al. introduce a gene-silencing method that uses 'U1 adaptors' to block polyadenylation of pre-mRNA in the nucleus. Silencing is stronger when U1 adaptors are combined with siRNAs than when either is used alone.

    • Rafal Goraczniak
    • Mark A Behlke
    • Samuel I Gunderson
    Article

  • Keng et al. characterize the mouse hepatocellular carcinoma genome by using tissue-specific recombinase expression to restrict mobilization of the Sleeping Beauty transposon to the liver. High throughput sequencing of >100,000 insertions sites in mouse tumor nodules identifies potential therapeutic targets.

    • Vincent W Keng
    • Augusto Villanueva
    • David A Largaespada
    Article
Top of page ⤴

Letter

Top of page ⤴

Careers and Recruitment

Top of page ⤴

People

Top of page ⤴

Search

Advanced search

Quick links